Market Place
Sourcing Support
Dermavant Presents VTAMA® Data for Atopic Dermatitis at Conference
25 Oct 2024 //
BUSINESSWIRE
Dermavant Presents On Itch & Sleep Improves In Atopic Dermatitis
24 Oct 2024 //
BUSINESSWIRE
Organon pays up to $1.2B to acquire Dermavant and its steroid-free cream Vtama
19 Sep 2024 //
REUTERS
Dermavant announces approval of Tapinarof for psoriasis and atopic dermatitis
25 Jun 2024 //
BUSINESSWIRE
Dermavant VTAMA Atopic Dermatitis Data Published In JAAD
21 May 2024 //
BUSINESSWIRE
Dermavant`s VTAMA® sNDA Accepted for Atopic Dermatitis in ?2 Years
29 Apr 2024 //
BUSINESSWIRE
Dermavant Submits sNDA for VTAMA Cream for the Treatment of Atopic Dermatitis
14 Feb 2024 //
BUSINESSWIRE
Dermavant Announces Positive Data from Phase 3 in Atopic Dermatitis with VTAMA®
11 Jan 2024 //
BUSINESSWIRE
Dermavant`s Vtama excels in another trial in atopic dermatitis
11 Jan 2024 //
FIERCE PHARMA
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA
06 Dec 2023 //
BUSINESSWIRE
Dermavant CEO draws Botox comparison to instill Vtama confidence
28 Nov 2023 //
FIERCE PHARMA
With Dermavant`s Vtama struggling, Leerink slashes projections
14 Nov 2023 //
FIERCE PHARMA
Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA
20 Oct 2023 //
BUSINESSWIRE
Dermavant to Present New Positive Data from Phase 4 of VTAMA
16 Oct 2023 //
BUSINESSWIRE
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023
13 Oct 2023 //
BUSINESSWIRE
Dermavant Announces New Positive Pruritus Data for VTAMA
12 Oct 2023 //
BUSINESSWIRE
Dermavant strengthens approval bid for Vtama in eczema
12 Oct 2023 //
FIERCE PHARMA
Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA
06 Oct 2023 //
BUSINESSWIRE
Dermavant Appoints John Darden as New Head of Marketing
05 Oct 2023 //
BUSINESSWIRE
Dermavant taps AI for ‘white-glove’ website service for Vtama psoriasis med
12 Jul 2023 //
ENDPTS
Dermavant Reports Positive Topline Results from ADORING 1
16 May 2023 //
BUSINESSWIRE
Dermavant bolsters Vtama`s case for approval in eczema
16 May 2023 //
FIERCE PHARMA
Dermavant Reports Results from ADORING 2 Atopic Dermatitis PIII of VTAMA
15 Mar 2023 //
BUSINESSWIRE
Dermavant`s Vtama cream hits goal in first eczema phase 3 study
15 Mar 2023 //
FIERCE PHARMA
Dermavant to Present Data from Multiple Studies of VTAMA
10 Mar 2023 //
BUSINESSWIRE
Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA cream
13 Feb 2023 //
BUSINESSWIRE
Dermavant to Present Data from Multiple Studies of VTAMA cream
12 Jan 2023 //
BUSINESSWIRE
Dermavant launches first streaming commercial for Vtama
29 Nov 2022 //
FIERCEPHARMA
Dermavant Launches First Commercial for VTAMA (tapinarof) cream
22 Nov 2022 //
BUSINESSWIRE
Dermavant Announces Highly Favorable Results from Pediatric Maximal of VTAMA®
08 Nov 2022 //
BUSINESSWIRE
Dermavant to Present Data from Multiple Clinical Trials of VTAMA at
13 Oct 2022 //
BUSINESSWIRE
Dermavant to Present New Data from Phase 3 Trial Program of VTAMA cream
24 Aug 2022 //
BUSINESSWIRE
VTAMA (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD
28 Jun 2022 //
BUSINESSWIRE
FDA Approves Dermavant`s VTAMA (tapinarof) cream for Psoriasis in the U.S.
24 May 2022 //
GLOBENEWSWIRE
Dermavant Shows Durability and Tolerability Data from Phase 3 PSOARING 3 Trial
25 Mar 2022 //
BUSINESSWIRE
Dermavant to Present New Data from Phase 3 Extension Trial of Tapinarof Cream
11 Mar 2022 //
BUSINESSWIRE
Dermavant Appoints Nancy Beesley to its Board of Directors
08 Mar 2022 //
BUSINESSWIRE
Dermavant Presents NPS Data from PSOARING 3 Long Term Extension Trial
15 Jan 2022 //
BUSINESSWIRE
Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 WCDC
07 Jan 2022 //
BUSINESSWIRE
Even as topical, shaking JAK concerns may be tough for Opzelura
12 Nov 2021 //
FIERCEPHARMA
Dermavant New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof
30 Sep 2021 //
BUSINESSWIRE
Dermavant Announces First Patient Dosed in ADORING
09 Sep 2021 //
BIOSPACE
Dermavant Announces FDA Acceptance for Filing of NDA for Tapinarof Cream
10 Aug 2021 //
BUSINESSWIRE
Dermavant Announces $200 Million of Financing
07 Jun 2021 //
BUSINESSWIRE
Dermavant engineers $160M deal to pay off GlaxoSmithKline milestones
07 Jun 2021 //
ENDPTS
Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream
03 Jun 2021 //
BLOOMBERG
Dermavant Sciences announce data of two Phase III trials for psoriasis
26 Apr 2021 //
PHARMAFILE
Dermavant to Showcase PASI90, Itch and Quality of Life Data from Ph3 Trials
23 Apr 2021 //
BUSINESSWIRE
Dermavant to Showcase PASI90, Itch and Quality of Life Data Ph3 AAD VMX 2021
22 Apr 2021 //
PRNEWSWIRE
Dermavant Announces Tapinar of Data Presentations at the AAD VMX 2021
16 Apr 2021 //
BUSINESSWIRE
Dermavant Announces Tapinar of Data Presentation at the Innovations
11 Mar 2021 //
BUSINESSWIRE
Dermavant shows deepening effects on psoriasis ahead of NDA
18 Feb 2021 //
FIERCEBIOTECH
Positive Data from PSOARING 3 Support Long-Term Use of Tapinarof Cream
18 Feb 2021 //
BUSINESSWIRE
Dermavant Announces Tapinarof Data Presentation at Maui Derm for 2021
21 Jan 2021 //
BUSINESSWIRE
Dermavant’s Pivotal Phase 3 PSOARING Data for Tapinarof Cream
27 Oct 2020 //
BUSINESSWIRE
Dermavant’s Pivotal Phase 3 PSOARING Data for Tapinarof Cream
27 Oct 2020 //
BUSINESSWIRE
Dermavant Announces Presentation of Tapinarof Pivotal Ph3 PSOARING Data
22 Oct 2020 //
BUSINESSWIRE
Dermavant`s psoriasis cream hits the mark in phase 3, teeing up FDA filing
28 Aug 2020 //
FIERCE BIOTECH
Dermavant`s psoriasis cream hits the mark in phase 3, teeing up FDA filing
27 Aug 2020 //
FIERCE BIOTECH
Dermavant Announces Publication in JAAD of Tapinarof Cream phase 2
17 Jun 2020 //
PRESS RELEASE
